REFERENCES
1. Scott DL, White SP, Otwinowski Z, Yuan W, Gelb MH, Sigler PB. Interfacial catalysis: the mechanism of phospholipase A2. Science. 1990;250:1541-6.
2. Touqui L, Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med. 2001;1:739-54.
3. Hidalgo I, Sorolla MA, Sorolla A, Salud A, Parisi E. Secreted phospholipases A2: drivers of inflammation and cancer. Int J Mol Sci. 2024;25:12408.
4. Jaulmes A, Janvier B, Andreani M, Raymondjean M. Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:1161-7.
5. Beck S, Lambeau G, Scholz-Pedretti K, et al. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem. 2003;278:29799-812.
6. Lu S, Dong Z. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells. Int J Oncol. 2017;50:2113-22.
7. Fujita M, Zhu K, Fujita CK, et al. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1. J Biol Chem. 2015;290:259-71.
8. Lee LK, Bryant KJ, Bouveret R, et al. Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes. J Biol Chem. 2013;288:15269-79.
9. Mann TJ, Kim RR, Sajinovic M, et al. Targeting secreted PLA2 interactions with EGFR and vimentin to arrest prostate tumour growth. Cell Death Dis. 2026;17:183.
10. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem. 2000;275:22895-904.
11. Yang TT, Ung PM, Rincón M, Chow CW. Role of the CCAAT/enhancer-binding protein NFATc2 transcription factor cascade in the induction of secretory phospholipase A2. J Biol Chem. 2006;281:11541-52.
12. Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M, El Hadri K. Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. Mol Cell Biol. 2007;27:8374-87.
13. Sharma P, Thakran S, Deng X, Elam MB, Park EA. Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone. J Biol Chem. 2013;288:16321-33.
14. Sartipy P, Johansen B, Gâsvik K, Hurt-Camejo E. Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions. Circ Res. 2000;86:707-14.
15. Ganesan K, Ivanova T, Wu Y, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68:4277-86.
16. Leung SY, Chen X, Chu KM, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A. 2002;99:16203-8.
17. Xing XF, Li H, Zhong XY, et al. Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology. 2011;59:198-206.
18. Fijneman RJA, Peham JR, van de Wiel MA, et al. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008;99:2113-9.
19. Fijneman RJA, Bade LK, Peham JR, et al. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell Oncol. 2009;31:345-56.
20. Chen J, Wang D, Wu G, et al. STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A. J Exp Clin Cancer Res. 2024;43:260.
21. Ray U, Roy D, Jin L, et al. Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization. J Exp Clin Cancer Res. 2021;40:182.
22. Kudo K, Miki Y, Carreras J, et al. Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma. Cell Metab. 2022;34:615-33.e8.
23. Zhang T, Yu W, Cheng X, et al. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Sci Immunol. 2024;9:eadh2334.
24. Hui DY. Group 1B phospholipase A2 in metabolic and inflammatory disease modulation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:784-8.
25. Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257-70.
26. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174-86.
27. Cords L, Tietscher S, Anzeneder T, et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat Commun. 2023;14:4294.
28. Ge W, Yue M, Lin R, et al. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Cancer Lett. 2023;558:216095.
29. Dietze R, Hammoud MK, Gómez-Serrano M, et al. Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer. Theranostics. 2021;11:1377-95.
30. Varani J, McClintock SD, Nadeem DM, Harber I, Zeidan D, Aslam MN. A multi-mineral intervention to counter pro-inflammatory activity and to improve the barrier in human colon organoids. Front Cell Dev Biol. 2023;11:1132905.
31. Miki Y, Taketomi Y, Kidoguchi Y, et al. Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota. JCI Insight. 2022;7:e152611.
32. Zhang H, Qian Y, Zhang Y, et al. Multi-omics analysis deciphers intercellular communication regulating oxidative stress to promote oral squamous cell carcinoma progression. NPJ Precis Oncol. 2024;8:272.
33. Wang Z, Yan N, Sheng H, Xiao Y, Sun J, Cao C. Single-cell transcriptomic analysis reveals an immunosuppressive network between POSTN CAFs and ACKR1 ECs in TKI-resistant lung cancer. Cancer Genomics Proteomics. 2024;21:65-78.
34. Calabrese C, Miserocchi G, De Vita A, et al. Lipids and adipocytes involvement in tumor progression with a focus on obesity and diet. Obes Rev. 2024;25:e13833.
35. Jonker PB, Muir A. Metabolic ripple effects - deciphering how lipid metabolism in cancer interfaces with the tumor microenvironment. Dis Model Mech. 2024;17:dmm050814.
36. Aggarwal A, Guo DL, Hoshida Y, et al. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res. 2006;66:232-41.
37. Mounier CM, Wendum D, Greenspan E, Fléjou JF, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer. 2008;98:587-95.
38. Deng C, Zhong ME, Chen Y, et al. Proteomic profiling and functional characterization of serum-derived extracellular vesicles in the mucinous and non-mucinous colon adenocarcinoma. J Cancer Res Clin Oncol. 2023;149:9285-300.
39. Wang X, Liu C, Chen J, et al. Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma. Cell Discov. 2022;8:101.
40. Qiu C, Xiang YK, Da XB, et al. Phospholipase A2 enzymes PLA2G2A and PLA2G12B as potential diagnostic and prognostic biomarkers in cholangiocarcinoma. World J Gastrointest Surg. 2024;16:289-306.
41. Iwabuchi S, Takahashi K, Kawaguchi K, et al. Phospholipase A2 group IIA is associated with inflammatory hepatocellular adenoma. Cancers. 2024;16:159.
42. Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015;21:544-52.
43. Kim A, Lim SM, Kim JH, Seo JS. Integrative genomic and transcriptomic analyses of tumor suppressor genes and their role on tumor microenvironment and immunity in lung squamous cell carcinoma. Front Immunol. 2021;12:598671.
44. Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl. 2004;25:944-53.
45. Zhang Y, Kong X, Xin S, Bi L, Sun X. Discovery of lipid metabolism-related genes for predicting tumor immune microenvironment status and prognosis in prostate cancer. J Oncol. 2022;2022:8227806.
46. Niu W, Zhang T, Ma L. Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta. Sci Rep. 2023;13:2459.
47. Ozturk K, Onal MS, Efiloglu O, Nikerel E, Yildirim A, Telci D. Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis. Gene. 2020;742:144589.
48. Wang C, Zhang X, Zhu S, et al. Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis. Heliyon. 2024;10:e36156.
49. Tang F, Lu Z, He C, Zhang H, Wu W, He Z. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database. BMC Cancer. 2021;21:638.
50. Zhang W, Luo M, Xiong B, Liu X. Upregulation of metallothionein 1 G (MT1G) negatively regulates ferroptosis in clear cell renal cell carcinoma by reducing glutathione consumption. J Oncol. 2022;2022:4000617.
51. Zhou Z, Chai Y, Li Y, Zhang Y, Wang T. Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by NMF clustering and building related signature. Discov Oncol. 2024;15:796.
52. Meng Y, Yang Y, Zhang Y, Yang X, Li X, Hu C. The role of an immune signature for prognosis and immunotherapy response in endometrial cancer. Am J Transl Res. 2021;13:532-48.
53. Liu J, Chen X, Jiang Y, Cheng W. Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer. Int Immunopharmacol. 2020;86:106735.
54. Liu T, Liu C, Yan M, et al. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients. Nat Commun. 2022;13:6823.
55. Zhai Z, Mu T, Zhao L, et al. Stachydrine represses the proliferation and enhances cell cycle arrest and apoptosis of breast cancer cells via PLA2G2A/DCN axis. Chem Biol Drug Des. 2024;103:e14429.
56. Tabuso M, Adya R, Stark R, et al. Fibrotic phenotype of peritumour mesenteric adipose tissue in human colon cancer: a potential hallmark of metastatic properties. Int J Mol Sci. 2021;22:2430.
57. Chida K, Kawazoe A, Suzuki T, et al. Transcriptomic profiling of MSI-H/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy. Clin Cancer Res. 2022;28:2110-7.
